Manuscripts
Showing 1530 manuscripts.
HIV-1 Remission and Possible Cure in a Woman after Haplo-Cord Blood Transplant
Citation
Jingmei Hsu, Koen Van Besien, Marshall J. Glesby, Savita Pahwa, Anne Coletti, Meredith G. Warshaw, Lawrence D Petz, Theodore B. Moore, Ya Hui Chen, Suresh Pallikkuth, Adit Dhummakupt, Ruth Cortado, Amanda Golner, Frederic Bone, Maria Baldo, Marcie Riches, John W. Mellors, Nicole H. Tobin, Renee Browning, Deborah Persaud, Yvonne Bryson, IMPAACT P1107 Team. HIV-1 Remission and Possible Cure in a Woman after Haplo-Cord Blood Transplant. Cell. 2023. 186: 1115-1126.
Year
Journal
Study
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study
Citation
Adrie Bekker, Edmund V. Capparelli, Avy Violari, Mark F. Cotton, Mae Cababasay, Jiajia Wang, Ruth Mathiba, Lubbe Wiesner, Andrew Wiznia, Pearl Samson, Renee Browning, Jack Moye, Firdose L. Nakwa, Bobbie Graham, Eric Decloedt, Helena Rabie, Mark Mirochnick, Tim R. Cressey, IMPAACT P1106 team. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV. 2022. PMID: 27936233
Year
Journal
Study
Influence of NAT2 genotype and maturation on isoniazid exposure in low-birth-weight and preterm infants with or without HIV exposure
Citation
Agathe Béranger, Adrie Bekker, Belén P. Solans, Mark F. Cotton, Mark Mirochnick, Avy Violari, Jiajia Wang, Mae Cababasay, Lubbe Wiesner, Renee Browning, Jack Moye, Edmund V. Capparelli, Radojka M. Savic. Influence of NAT2 genotype and maturation on isoniazid exposure in low-birth-weight and preterm infants with or without HIV exposure. Clinical Infectious Diseases. 2022. PMID: 35134861
Year
Journal
Study
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Citation
J Lommerse, D Clarke, T Kerbusch, H Merdjan, H Witjes, H Teppler, M Mirochnick, EP Acosta, L Wenning, S Nachman, A Chain. Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing. CPT: pharmacometrics & systems pharmacology. 2019. 8: 643-653. PMID: 31215170
Journal
Study
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial
Citation
Ashenafi S Cherkos, Sylvia M LaCourse, Daniel A Enquobahrie, Barbra A Richardson, Sarah Bradford, Grace Montepiedra, Blandina T Mmbaga, Tapiwa Mbengeranwa, Gaerolwe Masheto, Patrick Jean-Phillippe, Nahida Chakhtoura, Gerhard Theron, Adriana Weinberg, Haseena Cassim, Mpho S Raesi, Elsie Jean, Deo Wabwire, Teacler Nematadzira, Lynda Stranix-Chibanda, Anneke C Hesseling, Linda Aurpibul, Amita Gupta, Grace John-Stewart, IMPAACT P1078 TB APPRISE Study Team. Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial. eClinicalMedicine. 2023. 58: 101912. PMID: 36969345
Year
Journal
Study
Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term
Citation
Ceejay L. Boyce, Ingrid A. Beck, Sheila M. Styrchak, Samantha R. Hardy, Jackson J. Wallner, Ross S. Milne, R. Leavitt Morrison, David Shapiro, Esaú C João, Mark Mirochnick, Lisa M. Frenkel. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term. PLoS One. 2022. 17: e0275254. PMID: 36166463
Year
Journal
Study
Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081
Citation
Conrado Milani Coutinho, Meredith G. Warshaw, Geraldo Duarte, Alice Stek, Avy Violari, Cristina B. Hofer, Jaime G. Deville, James Samwel Ngocho, José Henrique Pilotto, Mario Dias Correa Jr., David E. Shapiro, Trevon L. Fuller, Nahida Chakhtoura, Mark Mirochnick, Esaú C. João. Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081. Journal of Acquired Immune Deficiency Syndromes. 2022. 91: 403-409. PMID: 36049477
Year
Journal
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
Citation
Christine E MacBrayne, Richard M Rutstein, Andrew A Wiznia, Bobbie Graham, Carmelita G Alvero, Lee Fairlie, Kathryn Lypen, Kathleen H George, Ellen Townley, Jack Moye Jr., Diane G Costello, Christina A Reding, Cristina Barroso Hofer, Herta M Crauwels, Xavier Woot de Trixhe, Lotke Tambuyzer, Simon Vanveggel, Magda Opsomer, Jennifer J Kiser, IMPAACT P1090 Protocol Team. Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age. AIDS. 2021. 35: 1413-1421. PMID: 33831904
Year
Journal
Study
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
Citation
Stein Schalkwijk, Rob Ter Heine, Angela C Colbers, Alwin D R Huitema, Paolo Denti, Kelly E Dooley, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, Mark Mirochnick, David M Burger. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clinical Pharmacokinetics. 2018. 57: 1421-1433. PMID: 29520730
Year
Journal
Study
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling
Citation
Stein Schalkwijk, Rob Ter Heine, Angela Colbers, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, José Moltó, Mark Mirochnick, Mats O Karlsson, David M Burger. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy. 2019. 74: 1348-1356. PMID: 30715324